Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

58 citing papers in PubMed.

1. Enhancing Cancer Therapy with TLR7/8 Agonists: Applications in Vaccines and Combination Treatments.Cancers · 2025
   Review
2. Programmed Death-1 Ligand 1 Domain Organization, Signaling Motifs, and Interactors in Cancer Immunotherapy.Cancers · 2025
   Review
3. In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment.ACS biomaterials science & engineering · 2025
   Review
4. Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools.Biomarker research · 2025
   Review
5. The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.Korean journal of clinical oncology · 2024
   Review
6. Immune-related LncRNAs scores predicts chemotherapeutic responses and prognosis in cervical cancer patients.Discover oncology · 2024
   Article
7. Tumors Established in a Defective Immune Environment Reprogram the Oncogenic Signaling Pathways to Escalate Tumor Antigenicity.Biomedicines · 2024
   Article
8. Fundamentals and Applications of Focused Ultrasound-Assisted Cancer Immune Checkpoint Inhibition for Solid Tumors.Pharmaceutics · 2024
   Review
9. Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model.JID innovations : skin science from molecules to population health · 2024
   Article
10. A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study.The Journal of investigative dermatology · 2023
    Article
11. Mechanisms of HIF-driven immunosuppression in tumour microenvironment.Journal of the Egyptian National Cancer Institute · 2023
    Review
12. Introduction of an Ultraviolet C-Irradiated 4T1 Murine Breast Cancer Whole-Cell Vaccine Model.Vaccines · 2023
    Article
13. Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer.Pharmaceutics · 2023
    Review
14. TCGA RNA-Seq and Tumor-Infiltrating Lymphocyte Imaging Data Reveal Cold Tumor Signatures of Invasive Ductal Carcinomas and Estrogen Receptor-Positive Human Breast Tumors.International journal of molecular sciences · 2023
    Article
15. Curcuphenol possesses an unusual histone deacetylase enhancing activity that counters immune escape in metastatic tumours.Frontiers in pharmacology · 2023
    Article
16. Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy.Research (Washington, D.C.) · 2023
    Article
17. Exposure of Immunogenic Tumor Antigens in Surrendered Immunity and the Significance of Autologous Tumor Cell-Based Vaccination in Precision Medicine.International journal of molecular sciences · 2022
    Review
18. Mathematical modeling of cancer immunotherapy for personalized clinical translation.Nature computational science · 2022
    Article
19. Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy.International journal of molecular sciences · 2022
    Review
20. Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process.Cells · 2022
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract